containing 38 mM CaCl 2 . Pooled normal plasma contained 5496 U/mL PCHE, 6% albumin contained 544 U/mL PCHE. From the PCHE activity found in the clot supernatant (1156 ± 29 U/mL), the amount of fluid phase in the wells was calculated (xfold dilution of sample) to be about 80 µL for the 100 µL clots + 50 µL PBS and also about 80 µL for the 125 µL clots + 50 µL PBS, i.e. 30 µL of the adherent micro-clots are in the fluid phase.
Clot Lysis Enhancement by Contact Phase Activation
In duplicate, 50 µL sample (pooled normal human citrated plasma; frozen at -80°C) were incubated with 20 µL physiol. NaCl, 64 mM CaCl 2 with or without 100 µg/mL Polybrene ® (hexadimethrine bromide; Sigma, Deisenhofen, Germany) or with 20 µL Pathromtin SL ® (silicon dioxide particles, vegetable phospholipids, 2.4 g/L NaCl (MW = 58.4), 14.3 g/L Hepes, pH 7.6; DadeBehring, Marburg, Germany), 64 mM CaCl 2 (MW = 110.9) with or without 100 µg/mL Polybrene ® for 30 minutes (37°C) in 300 µL 96 wells-microtiter wells with flat bottom, resulting in the generation of microclots. Fifty microliters of 0 mM or 10 mM chloramine-T ® (MW = 281.6 in trihydrated form; Sigma) in PBS were added. After 30 minutes (37°C), 50 µL 0 IU/ml or 10 IU/mL u-PA (1 mg = 100,000 IU; MW = 54 000 D; medac, Hamburg, Germany) in 6% bovine serum albumin (BSA)-PBS (Sigma) were added. Two-chain u-PA was chosen because it is more stable than pro-u-PA; prourokinase is converted immediately into urokinase by the contact phase enzyme kallikrein (6) . The turbidity at 405 nm of the wells was determined after 0 to 170 hours (37°C), using a microtiter plate reader (Milenia, DPC Biermann, Los Angeles, USA). After 24-hour incubation, 10 µL 2.3% NaN 3 (MW = 65.0; Sigma) in physiologic saline were added.
Zero percent clot turbidity controls consisted of replacement of CaCl 2 ± Pathromtin by physiologic saline and addition of 28 mA if pathromtin was used (=own turbidity of 20 µL pathromtin). Lysable clot turbidity (percent of initial clot turbity) was calculated as 100fold the ratio between (well turbidity after incubation-0 % clot turbidity)/(initial well turbidity -0 % clot turbidity) = lysable clot turbidity ( Table 1 ). The 100% clot control was the initial turbidity of the wells, because the increase in lysable turbidity units was less than 15 % within 24 hours.
Dependence of Pathromtin Concentration
Fifty microliters 0% to 100% Pathromtin SL ® (diluted in physiologic saline) supplemented with 6% BSA, 38 mM CaCl 2 were incubated with 75 µL pooled normal plasma for 30 minutes (37°C). Fifty microliters 10 mM chloramine-T ® in PBS were added and incubated for 30 minutes (37°C). Fifty microliters 0 IU/mL, 10 IU/mL, or 100 IU/mL u-PA in 6 % BSA-PBS were added and the clot lysis was determined after 0 to 16 hours.
Dependence of Chloramine Amount
Seventy-five microliters pooled normal plasma were incubated with 50 µL PAC (50% Pathromtin SL ® containing 6% BSA, 38 mM CaCl 2 ) for 30 minutes (37°C) in microtiter plates with flat bottom. 50 µL 0 to 50 mM (= 0-2.5 µmoles) CT were added. After 30 minutes (37°C) 50 µL 0, 1, 10, 100, or 1000 IU/mL u-PA in BSA-PBS were added and the turbidity of the wells was determined after 0 to 28 days (37°C). The clot lysis was calculated as indicated in Table 1 . INOXCLA (10) and INOXCLA(100) were performed with n = 24 plasmas of healthy blood donors (5 mL citrated blood), varying the used chloramine amount from 0 to 1.5 µmoles.
Dependence of u-PA Concentration
Fifty microliters pooled normal human plasma were incubated with 50 µL PAC for 30 minutes (37°C) to generate adherent microclots. Fifty microliters 0, 5, 10, 20 mM (0, 0.25, 0.5, 1 µmoles) chloramine-T ® in PBS were added and incubated for 30 minutes (37°C). Then 50 µL 0 to 31.4 IU/mL u-PA in 6% BSA-PBS were added and the absorbance at 405 nm was determined after 0 and 16 hours (37°C). The clot lysis was calculated as indicated in Table 1 .
Fifty microliters pooled normal plasma were incubated with 50 µL Pathromtin SL ® containing 25 mM CaCl 2 and 6% BSA for 30 minutes (37°C) to generate adherent microclots. Fifty microliters 0, 5, 10, 20 mM (0, 0.25, 0.5, 1 µmoles) chloramine-T ® in PBS were added and incubated for 30 minutes (37°C). Then 50 µL 0 to 1000 IU/mL u-PA in 6% BSA-PBS were added and the absorbance at 405 nm was determined after 0, 40, 100, 160 minutes (37°C). The clot lysis was calculated as indicated in Table 1 .
Lysis of Nonadherent Microclots, Lysis Inhibition by PAI-2
Fifty microliters pooled normal citrated plasma were incubated sixfold with 50 µL 50% Pathromtin SL ® , 6% BSA, 25 mM CaCl 2 for 30 minutes (37°C) to generate nonadherent microclots in flat bottom microtiter plates (MaxiSorp NUNC, Wiesbaden, Germany); in contrast to adherent microclots, nonadherent microclots can be separated from the plate by hitting the plate once firmly onto absorbent paper). 50 µL 10 mM chloramine-T ® in PBS were added. The INOX-CLA is preferably performed with microtiter plates that enable the generation of adherent clots. However, also the lysis of nonadherent clots is of clinical importance, e.g. clots in pulmonary embolism often are nonadherent. After 30 minutes (37°C) 50 µL 0, 1, 10, 100, 1000 IU/mL u-PA in BSA-PBS, 50 µL 100 (u-PA inhibiting) units/mL plasminogen activator inhibitor (PAI)-2 (DadeBehring), or 50 µL 1 IU/mL u-PA, 100 U/mL PAI-2 in BSA-PBS were added and the turbidity of the wells (absorbance at 405 nm) was determined after 0 to 17 hours; after 24 hours, 10 µL 2.3% NaN 3 (Sigma) in physiologic saline were added and the well turbidity was determined after 0 to 19 days (37°C).
The 100% lysis (= 0% clot) control consisted of replacement of PAC by BSA-PBS and addition of 35 mA (own turbidity of pathromtin) to the measured absorbance; this corrected 100% lysis control was identical to the turbidity of the wells treated with 50 µL 100 IU/mL u-PA for 17 hours (37°C). The 100% clot control was the initial turbidity of the wells, because the increase in lysable turbidity units was less than 15% within 17 hours.
INOXCLA Precision and Normal Range
The coefficients of variation (CV) of INOXCLA were determined: pooled normal plasma, converted into adherent microclots, were analyzed tenfold intra-and inter-assay INOXCLA(10), IN-OXCLA(100). The mean-values (MV) and the CV-values were calculated (CV = 100 * SD/MV).
The INOXCLA was performed with 36 citrated plasmas of healthy blood donors (5 mL blood samples; the plasmas were 3 hours old or less; normal prothrombin time, activated partial thromboplastin time, antithrombin III). The normal range of INOXCLA as mean value (MV) ± standard deviation (SD) was calculated, considering the mean clot lysis as 100% of the normal activity.
INOXCLA Correlation with Fibrinogen, Plasminogen, and FIPA
The INOXCLA results for 39 normal samples were correlated to functional fibrinogen (modified Clauss-Method). These samples were also analyzed in the Fibrinolytic Parameters Assay (FIPA): 50 µL sample or 100% normal plasma pool were incubated with 50 µL 10 IU/mL u-PA, 1.1 mM tranexamic acid (MW = 157; Sigma), 6% BSA-PBS for 20 minutes (37°C). Then 50 µL 3 mM HD-Val-Leu-Lys-pNA (Haemochrom, Essen, Germany), 1.2 M KCl (MW = 74.6; Sigma), 0.45 M arginine, pH 8.7 (MW = 174.2; Sigma) were added and the increase in absorbance at 405 nm was monitored at 25°C. The plasmin activity results were compared to those generated in 100% normal plasma. Plasmatic plasminogen was determined chromogenically (DadeBehring).
RESULTS

Clot Lysis Enhancement by Contact Phase Activation
The u-PA reagent with 10 IU/mL u-PA only induces thrombolysis, if the clot is oxidized (Fig.  1a ). Without pathromtin and without oxidant, the lysable clot turbidity increases to about 120% of the initial value in absence or presence of polybrene within 170 hours. Addition of pathromtin results into a 5% to 10% increase of lysable clot turbidity within 12 hours (Fig. 1a ). The 100% lysable clot turbidity for 50 µL normal plasma was 310 ± 18 mA, 0% clot turbidity for 50 µL pooled normal plasma was 321 ± 10 mA.
Dependence of Pathromtin Concentration
Fifty percent pathromtin was considered as the optimal pathromtin concentration: the clot lysis curve asymptotically approaches its maximum at pathromtin concentrations greater than 40%. Without pathromtin, clot lysis is about fivefold lower than with 50% to 100% pathromtin reagent ( Fig. 1b) .
Dependence of Chloramine Amount
The clot turbidity of normal plasma clots in dependence of incubation time and of oxidant concentration was studied. There appears to be a 10% increase in clot turbidity/µmol chloramine-T. In INOXCLA(10) the optimal chloramine amount added to the microclots is 0.5 to 1 µmol, that results in a greater than 100fold enhanced clot lysis after 16 hours compared to unoxidized clots ( Figs.  2a,b ). This oxidant amount results in a lysis of about 60% (i.e., 60 absolute %); oxidation by greater than 1.5 µmoles result in decreased clot lysis, the addition of 2.5 µmoles chloramine results in complete loss of lysis (Fig. 2b) . Also in INOX-CLA(100) the maximal lysis (about 60%) appears with 0.5 to 1 µmol chloramine (Figs. 3a,b) . In an INOXCLA(1000) version of the assay, 0.5 to 1 µmol is the optimal chloramine amount, resulting in a clot lysis of about 60% after 45 minutes (37°C) (Figs. 4a,b) . Figs. 2b, 3b, 4b, 5b ).
The INOXCLA(10) and INOXCLA(100) for 24 different blood donors with increasing test chloramine amounts showed that also here the clot lysis optimum is 0.5 to 1.0 µmol chloramine for each individual plasma.
Dependence of u-PA Concentration
Unoxidized clots are only lysed by >10% if the u-PA concentration in the reagent is greater than 16 IU/mL. If the u-PA concentration in the reagent is 16 IU/mL or less, oxidation of the clots with 0.5 to 1 µmoles chloramine enhances thrombolysis more than 100fold (Fig. 6a) . Figs. 6b-e demonstrate the lysis of unoxidized and oxidized microclots by 0 to 1000 IU/mL u-PA in the reagent after 10 minutes (Fig. 6b ), 40 minutes (Fig. 6c ), 100 minutes (Fig. 6d ), or 160 minutes (Fig. 6e) ; 100% lysable clot turbidity = 345 ± 9 mA. Fig. 7a demonstrates the lysis of normal oxidized nonadherent micro-clots by u-PA in the INOXCLA. Fifty percent clot lysis occurs after 0.5 hours, 1.5 hours, 7 hours, 5 days, or 9 days (37°C) when using 1000, 100, 10, 1, or 0 IU/mL u-PA reagent, respectively. The addition of 50 µL 1 IU/mL u-PA results in 5% to 10% lysis after 17 hours (37°C). If the 1 IU/mL u-PA reagent is supplemented with 100 U/mL PAI-2, nearly no clot lysis occurs within 19 days (37°C). Then 50 µL 0-31.4 IU/mL u-PA in 6% BSA-PBS were added and the absorbance at 405 nm was determined after 0 and 16 hours (37°C). The clot lysis was calculated as indicated in Table 1 (a) . Fifty microliters normal plasma were incubated with 50 µL Pathromtin SL ® containing 25 mM CaCl 2 and 6% BSA for 30 minutes (37°C): 0 (O), 0.25 (■), 0.5 (•), 1 µmoles (▲) chloramine-T ® in PBS were added and incubated for 30 minutes (37°C). Then 50 µL 0-1000 IU/mL u-PA in 6% BSA-PBS were added and the absorbance at 405 nm was determined after 0, 10 minutes (b), 40 minutes (c), 100 minutes (d), 160 minutes (e) (37°C). The clot lysis was calculated as indicated in Table 1 . Table 1 .
Lysis of Nonadherent Microclots
7a 7b Fig. 7b shows the lysis of normal oxidized nonadherent micro-clots with 50 µL of 1 IU/mL u-PA, 0 IU/mL u-PA, 1 IU/mL u-PA + 100 U/mL PAI-2, or 100 U/mL PAI-2; after 3 days (37°C), about 20% of the oxidized normal clot is lysed when using 50 µL 1 IU/mL u-PA. Without addition of u-PA, about 20% of the oxidized normal clot is lysed after 7 days (37°C). Clot lysis is completely inhibited by addition of 50 µL 100 U/mL PAI-2.
INOXCLA Precision and Normal Range
The intra-assay CV values for adherent thrombi of pooled normal plasma in the INOXCLA (10) and INOXCLA(100) are 5.7% and 3.8%, respectively. The inter-assay CV values are 8.6% and 6.1%, respectively. The normal range (MV ± SD) for INOXCLA(10) is 100 ± 25% (relative to the MV = 58 absolute % lysis), the normal range for INOXCLA(100) is 100 ± 25% (relative to the 0 = 63% lysis).
INOXCLA Correlation with Fibrinogen, Plasminogen, and FIPA
The FIPA results for 36 blood donors were 103 ± 28% of norm (generated linear plasmin activity: 6 mA/min (RT)). Functional plasminogen in 39 blood donors was 94 ± 20% of norm. Plasminogen correlated with FIPA with r = 0.735. The FIPA kinetic was linear up to an absorbance increase of about 1000 mA, which corresponds to about 40% of the maximal absorbance increase under this assay condition (max. ΔA = 2500 mA for 50 µL 3 mM Val-Leu-Lys-pNA). The INOXCLA(10) correlated with plasminogen and FIPA with r = 0.290 and r = 0.077, respectively. The INOX-CLA(100) correlated with plasminogen and FIPA with r = 0.405 and r = 0.367, respectively.
The lysable clot turbidity correlated with r = -0.375 to the INOXCLA (10) and with r= -0.433 to the INOXCLA (100). The lysable clot turbidity correlated with r = 0.682 to the plasmatic fibrinogen concentration. The 10 IU/mL u-PA reagent INOXCLA results correlated with r = 0.513 with those of the 100 IU/mL u-PA reagent.
DISCUSSION
Activated granulocytes are important effectors of cellular fibrinolysis (1-5); the cellular fibrinolysis seems to be of greater importance than the plasmatic one (7) . Main products of these cells are pro-urokinase, which is immediately converted to urokinase by the intrinsic contact enzyme kallikrein (6) or by plasmin, and NADPH-oxidase + myeloperoxidase. The latter generate superoxide anion (O 2 -⋅), H 2 O 2, HOCl, chloramines, and singlet oxygen ( 1 O 2 ). The fibrinolytic and the oxidative pathway are coupled (8) . In the human organism, 1 O 2 is produced by spontaneous dismutation of superoxide anion (O 2 -⋅) (9,10), by redox-cycling (11, 12) , or by interaction of HOCl or chloramines with H 2 O 2 (Mallet-reaction) (13) (14) (15) (16) .
The 1 O 2 generator chloramine strongly enhances u-PA-mediated lysis of plasma clots, which were generated by activation of the contact phase of coagulation, the intrinsic hemostasis; from these results, a new hemostasis assay has been derived: the intrinsic oxidative clot lysis assay (INOXCLA)-the clot turbidity, being the tool to determine the clot mass or clot lysis.
This technique is a further global fibrinolysis assay, in addition to the chromogenic FIPA (17) and other arginine-based hemostasis assays (18) (19) (20) , the INOXCLA allows global study of the lysis of individual patient clots by fibrinolytics.
The main regulator proteins of plasmatic fibrinolysis are PAI-1 and α2-antiplasmin (21) . These serine protease inhibitors are oxidatively inactivated by > 70% by 5 mM chloramine blood concentration (22, 23) . Oxidative destruction of PAI-1 is of much greater importance in INOX-CLA(10) than in INOXCLA(100) or INOX-CLA(1000) because the normal activity of PAI-1 is only about 1 u-PA inhibiting unit/mL plasma. Singlet oxygen quenchers in blood are proteins, containing methionine or cysteine residues, and unsaturated fatty acids or cholesterol (11, 24, 25) . Activated PMN generate about 5 to 10 mM HOCl/chloramines in their microenvironment (26). 1 O 2 -similar to the prooxidant nitric oxide (27)-is an antithrombotic (28): the ED 50 for inhibition of platelet aggregation in platelet-rich plasma is 1.0 mM chloramine; that for fibrinogen inactivation is 2.0 mM chloramine (29, 30) . The chloramine action against hemostasis proteins can be quenched by inhibitors of 1 O 2 but not by inhibitors of hydroxyl radicals, i.e. in contrast to HOCl, which is still partly radicalic, chloramines do not release oxygen radicals (29, 31) .
Hydroxyl radicals seem to be the most important oxygen species that damages tissue in ischemia (32) (33) (34) (35) . Vascular NADPH-oxidase generates reactive oxygen species that modulate hemostasis (36, 37) ; physiologically, NADPH-oxidase/myeloperoxidase might act anti-atherosclerotically (38) .
Fibrin activates PMN (3, (39) (40) (41) . Via 1 O 2 /photons, activated PMN call for thrombolysis amplification (3, 5, 12, 42, 43) , inhibit coagulation, enhance fibrinolysis (44, 45) , and shift hemostasis into an antithrombotic state. Imitation of the physiologic cellular thrombolysis might be of diagnostic or therapeutic importance.
